Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Dyax Corp has granted a non-exclusive license to Merck KGaA giving the German pharmaceutical firm access to its proprietary "phage display libraries" for the discovery and development of therapeutic antibodies and peptides.
Subscribe to our email newsletter
Under the terms of the agreement, Dyax receives an upfront technology license fee from Merck, as well as annual maintenance fees, clinical milestone payments and royalties on net sales of any products that may result from Merck’s use of the Dyax libraries. In addition, Merck has an option for Dyax to perform funded research on its behalf.
Henry Blair, chairman, president and CEO of Dyax commented, “I’m pleased with the steady growth in Dyax’s revenue-generating collaborations, as evidenced by this addition of Merck KGaA as a library licensee. This collaboration will allow Merck to utilize Dyax’s state-of-the-art libraries of fully human monoclonal antibodies, as well as our unique peptide libraries. We look forward to working with the Discovery team at Merck, and to the future potential to conduct funded research on their behalf.”
Dyax Corp is focused on advancing novel biotherapeutics for unmet medical needs, with an emphasis on cancer and inflammatory indications.